In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altermune Technologies LLC

www.altermune.com

Latest From Altermune Technologies LLC

Venture Funding Deals, February 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.

BioPharmaceutical Medical Device

Deal Watch: Acorda Places Another Bet In Neurology With Biotie Tender

Following the dissolution of its partnership with Sanofi, MannKind's next gambit is licensing its dry-powder delivery technology to new company Receptor Life Sciences. We also highlight our sister publication IN VIVO's deal of the year winners in the alliance, M&A and financing categories.

BioPharmaceutical Deals

Selected Start-Ups (10/2011)

In Vivo briefly describes these recently founded companies: Altermune Technologies, Ariel Pharmaceuticals, AUM Cardiovascular, BioMoti, Tensha Therapeutics and Trevi Therapeutics.

Recent Financings of Private Companies (10/2011)

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Altermune Technologies LLC
  • Senior Management
  • Kary B Mullis, PhD, CSO
    Charles Roberts, PhD, Pres.
  • Contact Info
  • Altermune Technologies LLC
    Phone: 207 4092992
    co Loxbridge Research
    21 Albemarle St
    London, CA W1S 4BS
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register